Rockville, Md. (December 20, 2022) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, today announced the United States Patent Office (USPTO) issued a patent, entitled Materials and Methods for Manufacturing Blood Products (Patent 11,529,587 B2 ('587 Patent) covering a new innovation in the method used to produce Thrombosomes®. Thrombosomes is a novel, shelf-stable hemostatic agent currently in Phase II clinical trials.
"This patent provides protection to our core technology through 2041 further demonstrating Cellphire Therapeutics’ emphasis on innovation and our ability to develop unique intellectual property,” said Keith Moskowitz, VP of Discovery and Research. “Cellphire anticipates further advances in Thrombosomes’ U.S. and global patent protection later in 2023."
"This is an important milestone for the company on the road to achieving our mission of saving lives with our cellular therapeutics,” said Mike Gaffney, Cellphire Therapeutics CEO. “We appreciate and thank our collaborators, federal funding agencies, and our team for helping us realize this achievement.”
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications for Orphan populations to surgical, trauma, traumatic brain injury (TBI) and intercranial hemorrhage (ICH) unmet clinical needs, among other things. For more information, visit www.cellphire.com.
The Thrombosomes project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021C.
Media and Investor Relations
Director, Business Operations